Carles Aracil

5.0k total citations · 2 hit papers
36 papers, 3.0k citations indexed

About

Carles Aracil is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Carles Aracil has authored 36 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Hepatology, 27 papers in Epidemiology and 18 papers in Surgery. Recurrent topics in Carles Aracil's work include Liver Disease and Transplantation (28 papers), Liver Disease Diagnosis and Treatment (27 papers) and Organ Transplantation Techniques and Outcomes (15 papers). Carles Aracil is often cited by papers focused on Liver Disease and Transplantation (28 papers), Liver Disease Diagnosis and Treatment (27 papers) and Organ Transplantation Techniques and Outcomes (15 papers). Carles Aracil collaborates with scholars based in Spain, Switzerland and United States. Carles Aracil's co-authors include Càndid Villanueva, María Poca, Carlos Guarner, Alan Colomo, Virginia Hernández–Gea, Isabel Graupera, Cristina Álvarez–Urturi, Juan G. Abraldeṣ, Rafael Bañares and Juan Carlos García‐Pagán and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Carles Aracil

34 papers receiving 2.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transfusion Strategies for Acute Upper Gastrointestinal Bleeding

2013 1.0k citations Càndid Villanueva, Alan Colomo et al. profile →
β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial

2019 392 citations Càndid Villanueva, Agustı́n Albillos et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carles Aracil Spain	19	2.0k	1.9k	1.4k	466	429	36	3.0k
María Poca Spain	18	1.4k 0.7×	1.4k 0.7×	939 0.7×	467 1.0×	300 0.7×	50	2.4k
Alan Colomo Spain	9	743 0.4×	721 0.4×	679 0.5×	466 1.0×	296 0.7×	15	1.6k
Carlos Guarner‐Argente Spain	22	597 0.3×	574 0.3×	1.4k 1.0×	466 1.0×	439 1.0×	65	2.6k
Mar Concepción Spain	10	444 0.2×	433 0.2×	549 0.4×	466 1.0×	257 0.6×	15	1.4k
Cristina Álvarez–Urturi Spain	6	429 0.2×	434 0.2×	482 0.3×	468 1.0×	267 0.6×	10	1.3k
Patrick G. Northup United States	38	3.7k 1.8×	3.0k 1.6×	2.3k 1.6×	54 0.1×	117 0.3×	122	5.2k
Jordi Gordillo Spain	6	350 0.2×	346 0.2×	404 0.3×	466 1.0×	253 0.6×	9	1.2k
Annabel Blasi Spain	22	747 0.4×	599 0.3×	635 0.5×	123 0.3×	54 0.1×	83	1.4k
Alba Fernández Bosch Spain	5	245 0.1×	259 0.1×	418 0.3×	532 1.1×	252 0.6×	10	1.2k
Miquel Santaló Spain	8	246 0.1×	283 0.2×	395 0.3×	464 1.0×	252 0.6×	14	1.3k

Countries citing papers authored by Carles Aracil

Since Specialization

Citations

This map shows the geographic impact of Carles Aracil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carles Aracil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carles Aracil more than expected).

Fields of papers citing papers by Carles Aracil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carles Aracil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carles Aracil. The network helps show where Carles Aracil may publish in the future.

Co-authorship network of co-authors of Carles Aracil

This figure shows the co-authorship network connecting the top 25 collaborators of Carles Aracil. A scholar is included among the top collaborators of Carles Aracil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carles Aracil. Carles Aracil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bertot, Luis Calzadilla, Anna Sòria, Isabel Badell, et al.. (2025). Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model. Alimentary Pharmacology & Therapeutics. 62(5). 526–535.

Sorolla, Maria Alba, Eva Parisi, Anabel Sorolla, et al.. (2025). Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. Journal for ImmunoTherapy of Cancer. 13(3). e010024–e010024. 2 indexed citations

Villanueva, Càndid, Joan Genescà, Juan Carlos García‐Pagán, et al.. (2024). Progressive systemic inflammation precedes decompensation in compensated cirrhosis. JHEP Reports. 7(2). 101231–101231. 4 indexed citations

Alvarado‐Tápias, Edilmar, Anna Brujats, Ángela Puente, et al.. (2024). Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial. Hepatology. 82(1). 140–154. 6 indexed citations

Sorolla, Maria Alba, Eva Parisi, Anabel Sorolla, et al.. (2023). PD-2 Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies. Annals of Oncology. 34. S1–S1.

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2021). Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. Journal of Hepatology. 75(3). 589–599. 39 indexed citations

Alvarado‐Tápias, Edilmar, Alba Ardèvol, Oana Pavel, et al.. (2020). Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. Journal of Hepatology. 73(4). 829–841. 36 indexed citations

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2019). β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 393(10181). 1597–1608. 392 indexed citations breakdown →

Ardèvol, Alba, Gemma Ibáñez‐Sanz, Carles Aracil, et al.. (2017). Survival of patients with cirrhosis and acute peptic ulcer bleeding compared with variceal bleeding using current first‐line therapies. Hepatology. 67(4). 1458–1471. 44 indexed citations

10.

Fernández, Javier, Carles Aracil, Elsa Solà, et al.. (2016). Evaluación y tratamiento del paciente cirrótico crítico. Gastroenterología y Hepatología. 39(9). 607–626. 9 indexed citations

11.

Villanueva, Càndid, Agustı́n Albillos, Joan Genescà, et al.. (2015). Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension. Hepatology. 63(1). 197–206. 132 indexed citations

12.

Puente, Ángela, Virginia Hernández–Gea, Isabel Graupera, et al.. (2013). Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver International. 34(6). 823–833. 84 indexed citations

13.

Bosch, Jaime, Juan G. Abraldeṣ, Agustı́n Albillos, et al.. (2012). Hipertensión portal:: recomendaciones para su evaluación y tratamiento: documento de consenso auspiciado por la AEEH y el CIBERehd. 35(6). 421–450. 4 indexed citations

14.

Hernández–Gea, Virginia, Carles Aracil, Alan Colomo, et al.. (2012). Development of Ascites in Compensated Cirrhosis With Severe Portal Hypertension Treated With β-Blockers. The American Journal of Gastroenterology. 107(3). 418–427. 94 indexed citations

15.

Villanueva, Càndid, Carles Aracil, Alan Colomo, et al.. (2009). Acute Hemodynamic Response to β-Blockers and Prediction of Long-term Outcome in Primary Prophylaxis of Variceal Bleeding. Gastroenterology. 137(1). 119–128. 149 indexed citations

16.

Villanueva, Càndid, Carles Aracil, Alan Colomo, et al.. (2009). CLINICAL—LIVER, PANCREAS, AND BILIARY TRACT Acute Hemodynamic Response to -Blockers and Prediction of Long-term Outcome in Primary Prophylaxis of Variceal Bleeding. 1 indexed citations

17.

Villanueva, Càndid, Carles Aracil, Alan Colomo, et al.. (2008). Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient‐guided pharmacological therapy. Alimentary Pharmacology & Therapeutics. 29(4). 397–408. 40 indexed citations

18.

Turnés, Juan, Juan Carlos García‐Pagán, Carles Aracil, et al.. (2008). Portal Hypertension–Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation. Clinical Gastroenterology and Hepatology. 6(12). 1412–1417. 131 indexed citations

19.

Abraldeṣ, Juan G., Càndid Villanueva, Rafael Bañares, et al.. (2007). Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. Journal of Hepatology. 48(2). 229–236. 220 indexed citations

20.

Villanueva, Càndid, Marta Piqueras, Carles Aracil, et al.. (2006). A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding. Journal of Hepatology. 45(4). 560–567. 152 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact